Cencora Gestione
Criteri Gestione verificati 1/4
Cencora Il CEO è Bob Mauch, nominato in Oct2024, e ha un mandato di 1.75 anni. la retribuzione annua totale è $ 18.26M, composta da 7.4% di stipendio e 92.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.034% delle azioni della società, per un valore di $ 20.35M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 2.8 anni.
Informazioni chiave
Bob Mauch
Amministratore delegato
US$18.3m
Compenso totale
| Percentuale dello stipendio del CEO | 7.39% |
| Mandato del CEO | 1.8yrs |
| Proprietà del CEO | 0.03% |
| Durata media del management | 1.8yrs |
| Durata media del Consiglio di amministrazione | 2.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Seeking Alpha • Jul 22
Cencora: Specialty Infrastructure Is Rewriting The Distributor Model
Summary Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth. Execution risks include integration of acquisitions, increased leverage, regulatory scrutiny, and high customer concentration, but specialty platform buildout is expected to deepen margins and retention. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 22
COR: Fair Value View Will Weigh Nucleus Rollout And Cell Therapy Partnership
Analysts have raised their Cencora price target from $288.21 to $310.00, reflecting updated views on fair value, revenue, profit margins, and future P/E assumptions. What’s in the News for Cencora Cencora announced a multi-site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, with deployment planned in phases across more than 20 practice sites.Aggiornamento narrativa • Jul 08
COR: Insider Buying And Fair Value View Will Shape Upcoming Share Performance
Analysts have nudged their price target for Cencora higher from $280.00 to about $288.21, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What’s in the News for Cencora Cencora stock moved 3.6% higher on June 23, 2026, alongside commentary that the shares are viewed as modestly undervalued relative to one intrinsic value estimate and supported by what sources describe as solid business fundamentals.Articolo di analisi • Jun 16
Cencora (COR) Stock Could Be 20% Below Fair Value On Margin Growth Narrative
Cencora (COR) stock has drawn investor attention after recent trading performance, with the share price closing at $281.43. The move comes alongside mixed short term returns and a longer multi year track record. See our latest analysis for Cencora. Recent trading puts Cencora’s 30 day share price return at 9.20%, yet the stock is still down 16.95% year to date. Longer term total shareholder returns over three and five years remain positive, suggesting recent momentum is rebuilding after a...
Aggiornamento narrativa • Jun 15
COR: Buybacks And New CFO Appointment Will Support Long Term Upside
Analysts have modestly reduced their price target on Cencora to $350.58 from $356.83. This reflects slightly updated views on fair value and future P/E assumptions.Aggiornamento narrativa • Jun 01
COR: Buybacks And New CFO Will Support Long Term Upside
Analysts now estimate Cencora's fair value at $356.83 per share, down from $373.08. This change reflects updated assumptions around slightly slower revenue growth, a modestly lower profit margin outlook, and a small shift in future P/E expectations.Nuova narrativa • May 09
Specialty And AI Investments Will Shape A Stable Yet Constrained Future Trajectory
Catalysts About Cencora Cencora is a pharmaceutical services company that supports manufacturers, health systems, physician practices and pharmacies across the global pharmaceutical supply chain. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • May 08
COR: Share Repurchases And CFO Transition Will Support Long Term Upside
Analysts now estimate Cencora’s fair value at about $373, down from roughly $403. This reflects slightly higher assumed discount rates and a lower future P/E multiple, partly offset by a marginally stronger profit margin profile in their updated models.Aggiornamento narrativa • Apr 24
COR: CFO Transition And Disciplined Buybacks Will Support Long-Term Upside
Analysts have trimmed their price target on Cencora by about $5 to reflect slightly updated assumptions around fair value, revenue growth, profit margins, and future P/E, while still viewing the shares through a similar overall framework. What's in the News Cencora plans a leadership change, with long serving Chief Financial Officer James F.Aggiornamento narrativa • Apr 08
COR: Rare Disease Collaborations And Distribution Reach Will Support Long-Term Upside
Analysts have kept their price target for Cencora steady at $407.92, citing only very small tweaks to inputs like revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the business. What's in the News Cencora announced that Chief Financial Officer James F.Aggiornamento narrativa • Mar 25
COR: Rare Disease Partnerships Will Support Long-Term Upside For Capital Markets Access
Analysts have adjusted their fair value estimate for Cencora to about $408 from $410, reflecting small tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E rather than a major shift in the story. What's in the News Cencora plans for Chief Financial Officer James F.Aggiornamento narrativa • Mar 10
COR: Capital Markets And Rare-Disease Services Will Support Long-Term Upside
Analysts now place Cencora's fair value at $410.00, up from $403.79. This change reflects small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates in their models.Aggiornamento narrativa • Feb 24
COR: 3PL Expansion And M&A Options Will Shape Balanced Long-Term Upside
Analysts have nudged their price target for Cencora higher to about $404 from roughly $400, citing refreshed assumptions around revenue growth, profitability and a modestly higher future P/E multiple. What's in the News Cencora is expanding its third party logistics capabilities in the United States and Europe, including adding NextPharma Logistics across Germany, Austria and Switzerland and planning a new 3PL facility in Italy in 2026, alongside increased cold chain capacity across its European network (company announcement).Articolo di analisi • Feb 12
Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Cencora, Inc.'s ( NYSE:COR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...Aggiornamento narrativa • Feb 08
COR: Buybacks And 3PL Expansion Will Support Long-Term Upside Potential
Analysts have nudged their projected fair value for Cencora to $399.80 from $396.80, citing updated assumptions around revenue growth, profit margins, the discount rate and a slightly lower future P/E multiple. What's in the News Cencora completed a share repurchase program totaling 4,895,419 shares, or 2.49% of shares, for US$1,118.1m under the buyback announced on May 1, 2024 (Buyback Tranche Update).Aggiornamento narrativa • Jan 23
COR: Global 3PL Expansion And Logistics Investments Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about US$397 from roughly US$388. This reflects refreshed assumptions on revenue growth, profit margins and future P/E levels in their models.Aggiornamento narrativa • Jan 09
COR: Global 3PL Buildout And Higher Dividend Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about $388, citing slightly lower modeled revenue growth, a modestly stronger profit margin, and a small uptick in assumed future P/E as key drivers of the updated view. What's in the News Cencora announced investments to expand its third party logistics capabilities in the United States and Europe, including broader specialty logistics services for pharmaceutical companies worldwide.Aggiornamento narrativa • Dec 16
COR: Global 3PL Expansion And Dividend Increases Will Offset Goodwill Impairment Risks
Analysts have slightly raised their price target on Cencora, increasing fair value by about 1.8 dollars per share as they factor in marginally stronger projected revenue growth, a modestly higher long term profit margin, and a steady future earnings multiple. What's in the News Cencora is making major investments to expand its third party logistics network, including a new 500,000 square foot 3PL facility in Texas by 2028 and a tripling of ultra low and cryogenic storage capacity in the United States, to support growing demand for specialty medicines such as cell and gene therapies (company announcement).Aggiornamento narrativa • Dec 02
COR: Automated Distribution Expansion And Margins Will Balance Storage And Dividend Risks
Analysts have modestly raised their price target for Cencora, increasing the estimated fair value by $2.71 to $384.79. This adjustment is based on slight improvements in profit margin expectations and valuation multiples.Aggiornamento narrativa • Nov 18
COR: Automated Expansion And Margin Gains Will Offset Ongoing Legal Risks
Analysts have raised their price target for Cencora, increasing the estimated fair value from $338.29 to $382.07. They cite strengthened profit margin expectations, even though there is a slightly higher discount rate and moderated revenue growth forecasts.Aggiornamento narrativa • Nov 04
COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution
Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.Aggiornamento narrativa • Sep 04
Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery
With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.Articolo di analisi • Aug 09
Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NYSE:COR 1 Year Share Price vs Fair Value Explore Cencora's Fair Values from the Community and select yours Cencora...Seeking Alpha • Feb 25
Cencora: Great Track Record And Outlook, But Valuation Does Not Offer Upside
Summary Cencora has a solid industry position in an oligopolistic market with supernormal return ratios and solid stock price returns. 1QFY25 results, as well as the near-term outlook, are also solid, with EPS guided by management to grow in the low double digits in FY25. Moreover, the company also has a decent long-term outlook, with management as well as analysts guiding EPS to grow at an 8-12% growth rate. Despite a solid growth outlook, Cencora's valuation looks to have factored in much of these tailwinds, which has led me to issue a hold rating on the stock. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$3b |
| Dec 31 2025 | n/a | n/a | US$2b |
| Sep 30 2025 | US$18m | US$1m | US$2b |
| Jun 30 2025 | n/a | n/a | US$2b |
| Mar 31 2025 | n/a | n/a | US$2b |
| Dec 31 2024 | n/a | n/a | US$1b |
| Sep 30 2024 | US$9m | US$1m | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | n/a | n/a | US$2b |
| Sep 30 2023 | US$8m | US$975k | US$2b |
| Jun 30 2023 | n/a | n/a | US$2b |
| Mar 31 2023 | n/a | n/a | US$2b |
| Dec 31 2022 | n/a | n/a | US$2b |
| Sep 30 2022 | US$6m | US$850k | US$2b |
| Jun 30 2022 | n/a | n/a | US$2b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | n/a | n/a | US$2b |
| Sep 30 2021 | US$6m | US$800k | US$2b |
| Jun 30 2021 | n/a | n/a | -US$4b |
| Mar 31 2021 | n/a | n/a | -US$4b |
| Dec 31 2020 | n/a | n/a | -US$3b |
| Sep 30 2020 | US$4m | US$700k | -US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | n/a | n/a | US$649m |
| Sep 30 2019 | US$4m | US$675k | US$855m |
Compensazione vs Mercato: La retribuzione totale di Bob ($USD 18.26M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 14.63M ).
Compensazione vs guadagni: La retribuzione di Bob è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Bob Mauch (59 yo)
1.8yrs
Mandato
US$18,256,227
Compensazione
Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, served as an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 until September 2024 and...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 1.8yrs | US$18.26m | 0.034% $ 20.3m | |
| Executive VP & Chief Legal Officer | 4.8yrs | US$5.18m | 0.016% $ 9.6m | |
| Advisor | less than a year | US$6.52m | 0.082% $ 49.9m | |
| Advisor | no data | US$3.66m | 0.012% $ 7.3m | |
| Executive VP & CFO | less than a year | Nessun dato | 0% $ 0 | |
| Senior VP | 14.5yrs | Nessun dato | 0.0088% $ 5.3m | |
| Executive VP and Chief Data & Information Officer | 1.8yrs | Nessun dato | 0.0027% $ 1.6m | |
| Senior VP Of Investor Relations & Enterprise Productivity and Treasury | no data | Nessun dato | Nessun dato | |
| Executive VP & Chief Human Resources Officer | no data | Nessun dato | Nessun dato | |
| EVP and President of U.S. Pharmaceuticals & Animal Health | 1.8yrs | Nessun dato | Nessun dato | |
| EVP & President of International Business Group | 1.8yrs | Nessun dato | Nessun dato | |
| Executive VP and Chief Strategy and M&A Officer | 1.7yrs | Nessun dato | Nessun dato |
1.8yrs
Durata media
58.5yo
Età media
Gestione esperta: Il team dirigenziale di COR non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 1.8yrs | US$18.26m | 0.034% $ 20.3m | |
| Independent Director | 2.8yrs | US$360.94k | 0.00093% $ 563.0k | |
| Independent Chairman of the Board | 10.8yrs | US$375.22k | 0.016% $ 9.6m | |
| Independent Director | 13.2yrs | US$330.23k | 0.0088% $ 5.3m | |
| Independent Director | 6.5yrs | US$345.71k | 0.0064% $ 3.9m | |
| Independent Director | 1.1yrs | US$192.39k | Nessun dato | |
| Independent Director | 2.8yrs | US$383.10k | Nessun dato | |
| Independent director | 3.8yrs | US$330.23k | 0.000090% $ 54.5k | |
| Independent Director | less than a year | Nessun dato | 0% $ 0 | |
| Independent Director | 3.5yrs | US$385.23k | 0.00080% $ 484.3k | |
| Independent Director | 1.8yrs | US$396.44k | 0.00019% $ 115.0k |
2.8yrs
Durata media
63yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di COR non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/28 15:54 |
| Prezzo dell'azione a fine giornata | 2026/07/28 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/09/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cencora, Inc. è coperta da 30 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |